Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Jump Financial LLC

Jump Financial LLC lifted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 351.4% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 112,816 shares of the biopharmaceutical company's stock after buying an additional 87,825 shares during the quarter. Jump Financial LLC owned approximately 0.12% of Ultragenyx Pharmaceutical worth $4,746,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in RARE. Smartleaf Asset Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $35,000. Human Investing LLC purchased a new stake in Ultragenyx Pharmaceutical during the fourth quarter valued at $42,000. Van ECK Associates Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after purchasing an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Ultragenyx Pharmaceutical in the third quarter worth $83,000. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

Shares of RARE traded up $0.39 during trading hours on Tuesday, hitting $35.79. The stock had a trading volume of 334,337 shares, compared to its average volume of 807,657. The firm has a market capitalization of $3.36 billion, a price-to-earnings ratio of -5.64 and a beta of 0.61. The firm has a 50-day moving average price of $38.25 and a 200 day moving average price of $43.99. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). The business had revenue of $164.88 million for the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of several research analyst reports. Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright restated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler decreased their price objective on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Finally, JPMorgan Chase & Co. raised their price target on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $92.79.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now owns 54,991 shares in the company, valued at approximately $2,358,014.08. This trade represents a 5.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Richard Pinion sold 14,439 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $607,881.90. Following the transaction, the insider now owns 107,766 shares of the company's stock, valued at approximately $4,536,948.60. This represents a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock valued at $5,256,268 over the last ninety days. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.